SanBio Company Limited (TYO:4592)

Japan flag Japan · Delayed Price · Currency is JPY
1,678.00
+41.00 (2.50%)
Apr 3, 2025, 3:30 PM JST
292.97%
Market Cap 117.89B
Revenue (ttm) n/a
Net Income (ttm) -2.88B
Shares Out 72.01M
EPS (ttm) -41.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,142,100
Average Volume 4,095,945
Open 1,550.00
Previous Close 1,637.00
Day's Range 1,550.00 - 1,708.00
52-Week Range 380.00 - 1,850.00
Beta -0.08
RSI 77.53
Earnings Date Mar 17, 2025

About SanBio Company

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 29
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4592
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.